HUNTSVILLE, AL – Discovery Life Sciences™ (Discovery) announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government, and non-profit and academic research centers.

This innovative offering includes both exploratory and targeted proteomics using the Seer Proteograph™ Product Suite, SCIEX LC-MS/MS systems, Olink® Proximity Extension Assay (PEA), and Luminex xMAP® platforms.

Discovery’s proteomic service laboratories are now integrated with its market-leading short- and long-read genomic service laboratories and expansive global commercial biorepository of hyper-annotated® biospecimens.

“We are very excited to open our doors to researchers and scientists worldwide and provide them access to Discovery’s highly-scaled, multi-omic services to advance their biomarker discovery, clinical development, and large-scale research programs,” said Michael Pisano, Discovery’s executive vice president of Proteomics.

“Our proteomic experts carefully designed, built, and optimized a comprehensive, platform-agnostic suite of leading-edge proteomic and proteo-genomic technologies to support all biomarker strategies, large-scale population studies, and biobank characterization projects.”

As a part of its biomarker services expansion strategy, Discovery signed a multi-year agreement in January with Seer, Inc. (NASDAQ: SEER), a life science company commercializing a disruptive new platform for proteomics, and SCIEX, a global leader in life science analytical technologies, to form a first-of-its-kind Proteogenomics Consortium (PGC) for large-scale plasma proteomic studies.

The PGC combines the proprietary technologies and expertise of all three companies to offer unbiased, high-resolution proteogenomic services to help uncover novel biomarkers that can be mapped back to underlying genetic variations.

“The Proteogenomics Consortium strategically unites these highly advanced plasma proteomic technologies with our world-leading expertise in short- and long-read genomics to add deep, unbiased proteomics data more easily to discovery, translational, and clinical studies, as well as large-scale population research programs,” said Glenn Bilawsky, CEO of Discovery. “In addition, the PGC also enables the creation of new diagnostic tools for cancer, neurodegenerative, inflammatory, infectious diseases, and other therapeutic areas.”

Then, in September, Discovery announced it was the largest certified commercial service provider for the Olink® PEA platform in the Americas.

Olink’s PEA is a unique immuno-PCR technology that solves the dynamic range issue that has hindered plasma proteomics for decades, allowing for the detection and quantitation of low abundant proteins in plasma at scale.

Discovery will also implement complementary multiplex immunoassay platforms, including xMAP® technology from Luminex, enabling customizable protein and nucleic acid-based multiplex assays.

Discovery offers a wide range of services, including genomics, proteomics, pathology, and cell biology. Accompanying its extensive service portfolio, Discovery has the world’s largest commercial biorepository, offering partners a single chain of custody to accelerate clinical research and development.

Discovery’s integrated, multi-omic workflow enables clients to gain deeper insights while conserving precious samples.

For more information, please visit Discovery Life Science’s website here.